-
Study aim
-
The aim of this study is to determine the effects of magnesium oxid supplementation on gene expression related to insulin, lipid, and inflammation in diabetic hemodialysis patients
-
Design
-
Study design: Randomized double-blind placebo-controlled trial. Patients will be assigned into two groups to receive magnesium oxid supplement (n=30) or placebo (n=30).
-
Settings and conduct
-
Among Diabetic hemodialysis patients referred to Akhavan Clinic affiliated to Kashan University of Medical Sciences, 60 patients will be selected according to inclusion and exclusion criteria. Participants, investigators or the assessors of the outcomes are unaware of the study groups.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
1. Diabetic hemodialysis patients aged 45 to 75 years.
2. No smoking
3. Moderate hypertension (systolic blood pressure: 40-160 mmHg and diastolic blood pressure: 90-100 mmHg)
4. Not taking magnesium oxide supplements for the past 3 months
Exclusion criteria:
1. Patients taking antioxidant and/or anti-inflammatory supplements within 3 months prior to the intervention;
2.Hypo or hyperthyroidism
3. Specific disease leading to hospitalization
4. Hypertension (systolic blood pressure above 160 mmHg and diastolic blood pressure 100 mmHg)
-
Intervention groups
-
Intervention group: Magnesium oxid supplements (Barij Essence Co., Kashan, Iran), 250 µg, daily, for 24 weeks orally. Control group: Placebo (Barij Essence Co., Kashan, Iran), containing 100 mg of starch, daily, for 24 weeks orally.
-
Main outcome variables
-
Outcomes: Expressed levels of PPAR-γ gene (primary outcome) and gene expression related to inflammation and lipid (secondary outcomes) will be quantified at study baseline and end-of-trial.